Limits...
Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches.

Riedel RF - Cancer (2011)

Bottom Line: Efforts to increase response rates by using combination or dose-dense regimens have largely failed to improve patient outcomes.However, increasing evidence supports the use of specific treatments for certain histological subtypes of STS, and novel therapies, including tyrosine kinase and mammalian target of rapamycin inhibitors, are currently under active investigation.This article provides an overview of current systemic therapies for patients with advanced STS and discusses ongoing efforts designed to improve patient outcomes through the use of novel therapeutic agents and treatment strategies.

View Article: PubMed Central - PubMed

Affiliation: Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA. richard.riedel@duke.edu

Show MeSH

Related in: MedlinePlus

Elements of “watchful waiting” versus maintenance treatment are shown. Watchful waiting indicates first-line chemotherapy followed by monitoring until disease progression; maintenance treatment, first-line chemotherapy followed by maintenance therapy until disease progression.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3412982&req=5

fig01: Elements of “watchful waiting” versus maintenance treatment are shown. Watchful waiting indicates first-line chemotherapy followed by monitoring until disease progression; maintenance treatment, first-line chemotherapy followed by maintenance therapy until disease progression.

Mentions: Maintenance therapy has been developed as part of treatment paradigms to prolong response duration and delay disease progression in responsive patients or patients with SD after a defined number of chemotherapy cycles (Fig. .1). Given the inherent toxicity associated with first-line chemotherapy and the need to continue maintenance therapy for prolonged periods of time, agents used in maintenance therapy should be well tolerated. Some chemotherapeutic agents, as well as targeted therapies with cytostatic properties and documented tolerability, have been found to be effective as maintenance therapy in patients with non–small cell lung cancer and ovarian cancer.105-107 However, some studies have not demonstrated a benefit of maintenance therapy.108


Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches.

Riedel RF - Cancer (2011)

Elements of “watchful waiting” versus maintenance treatment are shown. Watchful waiting indicates first-line chemotherapy followed by monitoring until disease progression; maintenance treatment, first-line chemotherapy followed by maintenance therapy until disease progression.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3412982&req=5

fig01: Elements of “watchful waiting” versus maintenance treatment are shown. Watchful waiting indicates first-line chemotherapy followed by monitoring until disease progression; maintenance treatment, first-line chemotherapy followed by maintenance therapy until disease progression.
Mentions: Maintenance therapy has been developed as part of treatment paradigms to prolong response duration and delay disease progression in responsive patients or patients with SD after a defined number of chemotherapy cycles (Fig. .1). Given the inherent toxicity associated with first-line chemotherapy and the need to continue maintenance therapy for prolonged periods of time, agents used in maintenance therapy should be well tolerated. Some chemotherapeutic agents, as well as targeted therapies with cytostatic properties and documented tolerability, have been found to be effective as maintenance therapy in patients with non–small cell lung cancer and ovarian cancer.105-107 However, some studies have not demonstrated a benefit of maintenance therapy.108

Bottom Line: Efforts to increase response rates by using combination or dose-dense regimens have largely failed to improve patient outcomes.However, increasing evidence supports the use of specific treatments for certain histological subtypes of STS, and novel therapies, including tyrosine kinase and mammalian target of rapamycin inhibitors, are currently under active investigation.This article provides an overview of current systemic therapies for patients with advanced STS and discusses ongoing efforts designed to improve patient outcomes through the use of novel therapeutic agents and treatment strategies.

View Article: PubMed Central - PubMed

Affiliation: Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA. richard.riedel@duke.edu

Show MeSH
Related in: MedlinePlus